


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1-63. (canceled)

64. (previously presented) A compound of Formula (V):



or a pharmaceutically acceptable salt, solvate, hydrate or N-oxide thereof wherein:

R^2 is C_1 - C_6 alkyl with at least one hydrogen atom replaced by a substituent selected from the group consisting of $-\text{NR}^6\text{R}^7$, $-\text{OR}^8$, $-\text{CO}_2\text{R}^9$, $-\text{S}(\text{O})_2\text{R}^{10}$, $-\text{P}(\text{OR}^{11})\text{OR}^{12}$, aryl and substituted aryl;

R^4 is hydrogen, alkyl or substituted alkyl;

R^6 , R^7 , R^8 , R^9 , R^{10} , R^{11} and R^{12} are independently selected from the group consisting of hydrogen, acyl, substituted acyl, acyl chelate, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, imino and substituted imino;

R^{29} is C_1 - C_6 alkyl with at least one hydrogen atom replaced by $-\text{NHR}^{32}$;

R^{30} is acyl, substituted acyl, alkyl, substituted alkyl or a therapeutic agent;

R^{31} is hydrogen, alkyl, substituted alkyl or a therapeutic agent;

R^{32} is hydrogen, acyl, substituted acyl, alkyl, substituted alkyl or a therapeutic agent;

j and k are independently 0 or 1;


p and q are independently an integer between 0 and 100;

r and s are independently 0 or 1;


X_1 is $-\text{NH}(\text{C}=\text{C})_g\text{CO}-$, $-\text{NH}(\text{CH}_2)_h\text{CO}-$ or $-\text{NHCH}(\text{CH}_3)\text{CO}-$;

g and h are independently 1, 2, 3, 4, 5 or 6;


X_2 is



X_3 is




X₄ is



l is an integer from 1 to 4;

X₅ is




R¹³ is hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, arylalkyl, substituted arylalkyl, aryl or substituted aryl or -S(O)_xR¹⁴;

n is an integer from 1 to 5;

x and y are independently 0, 1 or 2;

R¹⁴ is alkyl, substituted alkyl, acyl, substituted acyl, arylalkyl, substituted arylalkyl, aryl or substituted aryl;

X₆ is



m is an integer from 1 to 4;

X₇ is -NH(C=C)_dCO-, -NH(CH₂)_eCO- or -NHCH(CH₃)CO; and

d and e are independently 1, 2, 3, 4, 5 or 6

with the proviso that at least one of R³⁰, R³¹ or R³² is present and is a therapeutic agent.


65. (previously presented) The compound of Claim 64, wherein

R² is C₁-C₄ alkyl with at least one hydrogen atom replaced by a substituent selected from the group consisting of -NR⁶R⁷, aryl and substituted aryl;

R⁴ is hydrogen;


X₁ is -NH(CH₂)_hCO-;

X₂ is




;

X₄ is




;

X₅ is



;

X₆ is



; and

X₇ is -NH(CH₂)_eCO-.

66. (original) The compound of Claim 65, wherein R¹³ is methyl or acetyl, s is 0, r is 0, R³⁰ is acetyl and R³¹ is a therapeutic agent.

67. (original) The compound of Claim 66, wherein the therapeutic agent is doxorubicin.

68. (previously presented) The compound of Claim 65, wherein R¹³ is methyl or hydrogen, s is 0,

r is 1, k is 1, e is 1, q is 2, R³⁰ is acetyl, R³¹ is hydrogen and R²⁹ is -(CH)₄NHR³².

69. (original) The compound of Claim 68, wherein the R³² is -CO(CH₂)₃-doxorubicin.

70. (original) The compound of Claim 68, wherein R³² is protoporphyrin.

71-74. (canceled)

75. (new) A compound of the following formula:

Ac-Pro-His-Ser-Cys(Ac)-Asn-doxorubicin.